Journal of Shanghai Jiao Tong University (Medical Science) >

2022 , Vol. 42 >Issue 2: 211 - 217

DOI: https://doi.org/10.3969/j.issn.1674-8115.2022.02.012

Review

Progress in research on the mechanism of drug resistance to conventional chemotherapeutic drugs in children with acute lymphoblastic leukemia

  • Yanyan LIN ,
  • Yan XU ,
  • Hui LI
Expand
  • Key Laboratory of Pediatric Hematology and Oncology of National Health Commission, Pediatric Translational Medicine Institute, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China
LI Hui, E-mail: lihui@scmc.com.cn.

Received date: 2021-09-06

  Online published: 2022-03-17

Supported by

National Natural Science Foundation of China(81870116);Rising-Star Program from the Science and Technology Commission of Shanghai Municipality(18QA1402900)

Fold

Abstract

Acute lymphoblastic leukemia (ALL) has the highest incidence of hematological tumors in children, accounting for about one-third of all childhood cancer cases. With the continuous optimization of the treatment plan and the expansion of health care coverage in China, remarkable improvements have been achieved in the treatment of childhood ALL, and the overall survival rate of more than 5 years has reached 90%. Lack of effective treatment and unacceptably high recurrence rate are the leading causes of severe decrease in the survival and quality of life of children with drug resistance. In recent years, pathogenesis and regulation mechanism of ALL drug resistance has become a hot topic and a difficulty of research at home and abroad. Studies have shown that children with ALL may not only antagonize a certain chemotherapy (chemotherapeutic) drug, but also have a thorny situation of multi-drug resistance. Therefore, it is of great significance to improve the research on the mechanism of drug resistance of ALL to improve the prognosis of children with ALL. This review summarizes recent research progress in drug resistance mechanisms of conventional chemotherapy drugs for childhood ALL, including hormones, antimetabolite drugs (folate antagonists, thiopurines, and amino acid metabolizing drugs), alkaloids and anthracyclines, in order to provide theoretical basis for coping with clinical drug resistance.

Key words： acute lymphoblastic leukemia; child; chemotherapy; drug-resistance mechanism; recurrence

Cite this article

Yanyan LIN , Yan XU , Hui LI . Progress in research on the mechanism of drug resistance to conventional chemotherapeutic drugs in children with acute lymphoblastic leukemia[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022 , 42(2) : 211 -217 . DOI: 10.3969/j.issn.1674-8115.2022.02.012

References

1 郑胡镛. 从北京儿童医院看儿童白血病治疗的发展[J]. 中国小儿血液与肿瘤杂志, 2019, 24(6): 282.
2 SHAHRIARI M, SHAKIBAZAD N, HAGHPANAH S, et al. Extramedullary manifestations in acute lymphoblastic leukemia in children: a systematic review and guideline-based approach of treatment[J]. Am J Blood Res, 2020, 10(6): 360-374.
3 TANG J, YU J, CAI J, et al. Prognostic factors for CNS control in children with acute lymphoblastic leukemia treated without cranial irradiation[J]. Blood, 2021, 138(4): 331-343.
4 PUI C H, YANG J J, BHAKTA N, et al. Global efforts toward the cure of childhood acute lymphoblastic leukaemia[J]. Lancet Child Adolesc Health, 2018, 2(6): 440-454.
5 蔡娇阳, 王宁玲, 蒋慧, 等. 儿童急性淋巴细胞白血病2005方案多中心远期临床报告[J]. 中华儿科杂志, 2018, 56(7): 511-517.
6 ROETEN M S F, VAN MEERLOO J, KWIDAMA Z J, et al. Pre-clinical evaluation of the proteasome inhibitor ixazomib against bortezomib-resistant leukemia cells and primary acute leukemia cells[J]. Cells, 2021, 10(3): 665.
7 OSKARSSON T, S?DERH?LL S, ARVIDSON J, et al. Treatment-related mortality in relapsed childhood acute lymphoblastic leukemia[J]. Pediatr Blood Cancer, 2018, 65(4): e26909.
8 BROWN P, INABA H, ANNESLEY C, et al. Pediatric acute lymphoblastic leukemia, version 2. 2020, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2020, 18(1): 81-112.
9 MESRIAN TANHA H, MOJTABAVI NAEINI M, RAHGOZAR S, et al. Integrative computational in-depth analysis of dysregulated miRNA-mRNA interactions in drug-resistant pediatric acute lymphoblastic leukemia cells: an attempt to obtain new potential gene-miRNA pathways involved in response to treatment[J]. Tumour Biol, 2016, 37(6): 7861-7872.
10 DE SMEDT R, MORSCIO J, GOOSSENS S, et al. Targeting steroid resistance in T-cell acute lymphoblastic leukemia[J]. Blood Rev, 2019, 38: 100591.
11 OLIVAS-AGUIRRE M, TORRES-LóPEZ L, POTTOSIN I, et al. Overcoming glucocorticoid resistance in acute lymphoblastic leukemia: repurposed drugs can improve the protocol[J]. Front Oncol, 2021, 11: 617937.
12 EMADALI A, HOGHOUGHI N, DULEY S, et al. Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms[J]. Blood, 2016, 127(24): 3040-3053.
13 XIAO H, DING Y, GAO Y, et al. Haploinsufficiency of NR3C1 drives glucocorticoid resistance in adult acute lymphoblastic leukemia cells by down-regulating the mitochondrial apoptosis axis, and is sensitive to Bcl-2 blockage[J]. Cancer Cell Int, 2019, 19: 218.
14 SAKURAI N, KOMADA Y, HANAKI R, et al. Role of microRNAs in glucocorticoid?resistant B?cell precursor acute lymphoblastic leukemia[J]. Oncol Rep, 2019, 42(2): 708-716.
15 LIANG Y N, TANG Y L, KE Z Y, et al. miR-124 contributes to glucocorticoid resistance in acute lymphoblastic leukemia by promoting proliferation, inhibiting apoptosis and targeting the glucocorticoid receptor[J]. J Steroid Biochem Mol Biol, 2017, 172: 62-68.
16 SCIARRILLO R, WOJTUSZKIEWICZ A, KOOI IE, et al. Glucocorticoid resistant pediatric acute lymphoblastic leukemia samples display altered splicing profile and vulnerability to spliceosome modulation[J]. Cancers, 2020, 12(3): 723.
17 ZHAO Q, ZHAO S, LI J, et al. TCF7L2 activated HOXA-AS2 decreased the glucocorticoid sensitivity in acute lymphoblastic leukemia through regulating HOXA3/EGFR/Ras/Raf/MEK/ERK pathway[J]. Biomed Pharmacother, 2019, 109: 1640-1649.
18 JING D, HUANG Y, LIU X, et al. Lymphocyte-specific chromatin accessibility pre-determines glucocorticoid resistance in acute lymphoblastic leukemia[J]. Cancer Cell, 2018, 34(6): 906-921.e8.
19 POULARD C, BAULU E, LEE BH, et al. Increasing G9a automethylation sensitizes B acute lymphoblastic leukemia cells to glucocorticoid-induced death[J]. Cell Death Dis, 2018, 9(10): 1038.
20 STEEGHS E M P, BOER J M, HOOGKAMER A Q, et al. Copy number alterations in B-cell development genes, drug resistance, and clinical outcome in pediatric B-cell precursor acute lymphoblastic leukemia[J]. Sci Rep, 2019, 9(1): 4634.
21 RODERICK J E, GALLAGHER K M, MURPHY L C, et al. Prostaglandin E2 stimulates cAMP signaling and resensitizes human leukemia cells to glucocorticoid-induced cell death[J]. Blood, 2021, 137(4): 500-512.
22 LIU Z, LI F, RUAN K, et al. Structural and functional insights into the human B?rjeson-Forssman-Lehmann syndrome-associated protein PHF6[J]. J Biol Chem, 2014, 289(14): 10069-10083.
23 XIANG J, WANG G, XIA T, et al. The depletion of PHF6 decreases the drug sensitivity of T-cell acute lymphoblastic leukemia to prednisolone[J]. Biomed Pharmacother, 2019, 109: 2210-2217.
24 LIU S G, YUE Z X, LI Z G, et al. β-catenin promotes MTX resistance of leukemia cells by down-regulating FPGS expression via NF-κB[J]. Cancer Cell Int, 2020, 20: 271.
25 WOJTUSZKIEWICZ A, RAZ S, STARK M, et al. Folylpolyglutamate synthetase splicing alterations in acute lymphoblastic leukemia are provoked by methotrexate and other chemotherapeutics and mediate chemoresistance[J]. Int J Cancer, 2016, 138(7): 1645-1656.
26 JARAMILLO A C, CLOOS J, LEMOS C, et al. Ex vivo resistance in childhood acute lymphoblastic leukemia: correlations between BCRP, MRP1, MRP4 and MRP5 ABC transporter expression and intracellular methotrexate polyglutamate accumulation[J]. Leuk Res, 2019, 79: 45-51.
27 MESRIAN TANHA H, RAHGOZAR S, MOJTABAVI NAEINI M. ABCC4 functional SNP in the 3' splice acceptor site of exon 8 (G912T) is associated with unfavorable clinical outcome in children with acute lymphoblastic leukemia[J]. Cancer Chemother Pharmacol, 2017, 80(1): 109-117.
28 XU H, ZHAO X J, BHOJWANI D, et al. ARID5B influences antimetabolite drug sensitivity and prognosis of acute lymphoblastic leukemia[J]. Clin Cancer Res, 2020, 26(1): 256-264.
29 TAMAI M, HUANG M, KAGAMI K, et al. Association of relapse-linked ARID5B single nucleotide polymorphisms with drug resistance in B-cell precursor acute lymphoblastic leukemia cell lines[J]. Cancer Cell Int, 2020, 20(1): 434.
30 XUE Y, RONG L C, TONG N, et al. CCND1 G870A polymorphism is associated with toxicity of methotrexate in childhood acute lymphoblastic leukemia[J]. Int J Clin Exp Pathol, 2015, 8(9): 11594-11600.
31 DIECK C L, FERRANDO A. Genetics and mechanisms of NT5C2-driven chemotherapy resistance in relapsed ALL[J]. Blood, 2019, 133(21): 2263-2268.
32 TZONEVA G, DIECK C L, OSHIMA K, et al. Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia[J]. Nature, 2018, 553(7689): 511-514.
33 MORIYAMA T, LIU S G, LI J, et al. Mechanisms of NT5C2-mediated thiopurine resistance in acute lymphoblastic leukemia[J]. Mol Cancer Ther, 2019, 18(10): 1887-1895.
34 TZONEVA G, PEREZ-GARCIA A, CARPENTER Z, et al. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL[J]. Nat Med, 2013, 19(3): 368-371.
35 BARZ M J, HOF J, GROENEVELD-KRENTZ S, et al. Subclonal NT5C2 mutations are associated with poor outcomes after relapse of pediatric acute lymphoblastic leukemia[J]. Blood, 2020, 135(12): 921-933.
36 HOVE-JENSEN B, ANDERSEN K R, KILSTRUP M, et al. Phosphoribosyl diphosphate (PRPP): biosynthesis, enzymology, utilization, and metabolic significance[J]. Microbiol Mol Biol Rev, 2017, 81(1). DOI:10.1128/mmbr.00040-16.
37 LI B, LI H, BAI Y, et al. Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL[J]. Nat Med, 2015, 21(6): 563-571.
38 EVENSEN N A, MADHUSOODHAN P P, MEYER J, et al. MSH6 haploinsufficiency at relapse contributes to the development of thiopurine resistance in pediatric B-lymphoblastic leukemia[J]. Haematologica, 2018, 103(5): 830-839.
39 YU S L, ZHANG H, HO B C, et al. FPGS relapse-specific mutations in relapsed childhood acute lymphoblastic leukemia[J]. Sci Rep, 2020, 10(1): 12074.
40 LEE J K, KANG S, WANG X, et al. HAP1 loss confers l-asparaginase resistance in ALL by downregulating the calpain-1-Bid-caspase-3/12 pathway[J]. Blood, 2019, 133(20): 2222-2232.
41 HINZE L, PFIRRMANN M, KARIM S, et al. Synthetic lethality of Wnt pathway activation and asparaginase in drug-resistant acute leukemias[J]. Cancer Cell, 2019, 35(4): 664-676.e7.
42 WILLIAMS R T, GUARECUCO R, GATES L A, et al. ZBTB1 regulates asparagine synthesis and leukemia cell response to L-asparaginase[J]. Cell Metab, 2020, 31(4): 852-861.e6.
43 ABERUYI N, RAHGOZAR S, POURABUTALEB E, et al. Selective dysregulation of ABC transporters in methotrexate-resistant leukemia T-cells can confer cross-resistance to cytarabine, vincristine and dexamethasone, but not doxorubicin[J]. Curr Res Transl Med, 2021, 69(1): 103269.
44 FU J Q, SI L B, ZHUANG Y, et al. Wnt/β?catenin inhibition reverses multidrug resistance in pediatric acute lymphoblastic leukemia[J]. Oncol Rep, 2019: 41(2): 1387-1394.
45 KARTNER N, RIORDAN J R, LING V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines[J]. Science, 1983, 221(4617): 1285-1288.
46 WEI L, SUN J, ZHANG N, et al. Noncoding RNAs in gastric cancer: implications for drug resistance[J]. Mol Cancer, 2020, 19(1): 62.
47 WEI L, WANG X, LV L, et al. The emerging role of noncoding RNAs in colorectal cancer chemoresistance[J]. Cell Oncol (Dordr), 2019, 42(6): 757-768.
48 CAPEL?A T, BENYAHIA Z, ZAMPIERI L X, et al. Metabolic and non-metabolic pathways that control cancer resistance to anthracyclines[J]. Semin Cell Dev Biol, 2020, 98: 181-191.
49 MORELL A, ?ERMáKOVá L, NOVOTNá E, et al. Bruton's tyrosine kinase inhibitors ibrutinib and acalabrutinib counteract anthracycline resistance in cancer cells expressing AKR1C3[J]. Cancers, 2020, 12(12): 3731.
50 NOVOTNá E, MORELL A, BüKüM N, et al. Interactions of antileukemic drugs with daunorubicin reductases: could reductases affect the clinical efficacy of daunorubicin chemoregimens? [J]. Arch Toxicol, 2020, 94(9): 3059-3068.
51 GAO C, LIU S G, LU W T, et al. Downregulating CREBBP inhibits proliferation and cell cycle progression and induces daunorubicin resistance in leukemia cells[J]. Mol Med Rep, 2020, 22(4): 2905-2915.
Options
Outlines

/

〈 〉